Skip to main content

Table 2 Multivariate Cox regression model for CRPC and overall mortality risk with PSAT½ groups as parameters

From: Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

  

CRPC

Overall mortality

 

Univariate

Multivariate

Univariate

Multivariate

p-value

HR

95% CI

p-value

p-value

HR

95% CI

p-value

Age

Continuous

0.204

0.995

0.970–1.022

0.734

0.243

1.046

0.990–1.105

0.107

Initial PSA

≥20 ng/mL

0.170

   

0.154

   

Gleason score

>7

0.013*

1.472

1.018–2.128

0.040*

0.006*

3.127

1.361–7.187

0.007*

PSAT½ (days)

Non-responder (below 0)

(reference)

   

(reference)

   

Ultra-rapid responder (0~15)

0.279

0.702

0.390–1.263

0.238

0.189

0.443

0.168–1.164

0.099

Rapid responder (15~30)

0.011*

0.499

0.271–0.920

0.026*

0.018*

0.295

0.109–0.797

0.016*

Intermediate responder (30~45)

0.007*

0.397

0.191–0.823

0.013*

0.011*

0.138

0.033–0.584

0.007*

Slow responder (over 45)

0.032*

0.553

0.289–1.057

0.070

0.094

0.501

0.183–1.368

0.177

Pathologic T stage

Below T2

(reference)

   

(reference)

   

T3

0.915

0.966

0.634–1.471

0.870

0.013*

4.987

1.187–20.946

0.028*

T4

0.034*

1.831

0.921–3.642

0.085

0.009*

9.521

1.799–50.402

0.008*

ADT exposure duration (days)

Continuous

0.169

   

0.386

   
  1. HR hazard ratio, CI confidence interval, PSA prostate-specific antigen, ADT androgen deprivation therapy, PSAT ½ prostate-specific antigen half-life
  2. *statistically significant at p < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us